Allarity Therapeutics vs Cardiff Oncology
ALLR and CRDF side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALLR and CRDF compare
Cardiff Oncology is the larger company, worth 5.0 times as much as Allarity Therapeutics ($69.4M against $13.8M).
Cardiff Oncology scores higher on the StockData Score (7 against 1 for Allarity Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALLR | CRDF |
|---|---|---|
| Size and price | ||
| Market cap | $13.8M | $69.4M |
| Share price | $0.865 | $0.893 |
| Change, 1 year | −24.1% | −56.2% |
| Change, 5 years | – | −84.1% |
| Beta (5Y) | 1.11 | 1.56 |
| Employees | 8 | 31 |
| StockData Score | ||
| Total score | 1 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 137× |
| P/B | 3.9× | 2.6× (better) |
| Growth | ||
| Revenue growth (TTM) | – | −7.0% |
| Revenue growth, 5Y average | – | 10.1% |
| Profitability | ||
| Operating margin | – | −8320% |
| Net margin | – | −7884% |
| Return on equity | −157% | −94.1% (better) |
| Return on invested capital | −957% | – |
| Financial health | ||
| Debt / equity | 5.90 (better) | 0.00 |
| Interest coverage | −10.1× | – |
| Current ratio | 1.11 | 3.30 (better) |
| Altman Z-score | −6.65 (better) | −16.00 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | 6.4% | – |
| Shareholder yield | 6.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 8.1% | 24.2% |
| Held by insiders | 6.3% | 4.9% |
| Insider net buying, 12 months | – | $1.1M |
| Short interest, % of float | 1.5% | 16.6% |
Go deeper
- ALLR stock overview
- ALLR income statement
- ALLR valuation and score
- CRDF stock overview
- CRDF income statement
- CRDF valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.